1. Home
  2. NLSP vs MGRX Comparison

NLSP vs MGRX Comparison

Compare NLSP & MGRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NLSP
  • MGRX
  • Stock Information
  • Founded
  • NLSP 2015
  • MGRX 2021
  • Country
  • NLSP Switzerland
  • MGRX United States
  • Employees
  • NLSP N/A
  • MGRX N/A
  • Industry
  • NLSP Biotechnology: Pharmaceutical Preparations
  • MGRX Computer Software: Prepackaged Software
  • Sector
  • NLSP Health Care
  • MGRX Technology
  • Exchange
  • NLSP Nasdaq
  • MGRX Nasdaq
  • Market Cap
  • NLSP 12.4M
  • MGRX 8.1M
  • IPO Year
  • NLSP 2021
  • MGRX 2023
  • Fundamental
  • Price
  • NLSP $2.50
  • MGRX $1.55
  • Analyst Decision
  • NLSP
  • MGRX
  • Analyst Count
  • NLSP 0
  • MGRX 0
  • Target Price
  • NLSP N/A
  • MGRX N/A
  • AVG Volume (30 Days)
  • NLSP 411.8K
  • MGRX 166.8K
  • Earning Date
  • NLSP 07-15-2025
  • MGRX 08-13-2025
  • Dividend Yield
  • NLSP N/A
  • MGRX N/A
  • EPS Growth
  • NLSP N/A
  • MGRX N/A
  • EPS
  • NLSP N/A
  • MGRX N/A
  • Revenue
  • NLSP N/A
  • MGRX $511,084.00
  • Revenue This Year
  • NLSP N/A
  • MGRX N/A
  • Revenue Next Year
  • NLSP N/A
  • MGRX N/A
  • P/E Ratio
  • NLSP N/A
  • MGRX N/A
  • Revenue Growth
  • NLSP N/A
  • MGRX N/A
  • 52 Week Low
  • NLSP $1.30
  • MGRX $1.32
  • 52 Week High
  • NLSP $15.59
  • MGRX $7.66
  • Technical
  • Relative Strength Index (RSI)
  • NLSP 52.64
  • MGRX 35.28
  • Support Level
  • NLSP $2.16
  • MGRX $1.46
  • Resistance Level
  • NLSP $3.08
  • MGRX $2.04
  • Average True Range (ATR)
  • NLSP 0.24
  • MGRX 0.17
  • MACD
  • NLSP -0.00
  • MGRX -0.06
  • Stochastic Oscillator
  • NLSP 30.21
  • MGRX 4.48

About NLSP NLS Pharmaceutics Ltd.

NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.

About MGRX Mangoceuticals Inc.

Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The company's platform provides access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED products.

Share on Social Networks: